Drugs / Umbilical Cord Mesenchymal Stem Cells
Umbilical Cord Mesenchymal Stem Cells
Trials 45
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06485648 | Oct 2024 → Oct 2026 expected | lupus nephritis | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT04457609 | Jul → Aug 2020 | COVID-19, pneumonia | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT04062136 | Mar 2019 → Nov 2020 | bronchopulmonary dysplasia | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1 | NCT02698813 | Dec 2016 → Dec 2018 | — | South China Research Center for Stem Cell and Regenerative Medicine | Unknown | No outcome recorded |
| Phase 1 | NCT02668068 | Jan 2016 → Mar 2019 | pneumoconiosis | Jianwu Dai | Completed | No outcome recorded |
| Phase 1 | NCT02834858 | Jan 2016 → Dec 2018 | ischemic disease, peripheral vascular disease | Jie Shen | Unknown | No outcome recorded |
| Phase 1 | NCT02235844 | Sep 2014 → Sep 2017 | Duchenne muscular dystrophy | Allergy and Asthma Consultants, Wichita, Kansas | Completed | No outcome recorded |
| Phase 1 | NCT01143168 | Aug 2010 → Aug 2011 | type 1 diabetes mellitus | Cellonis Biotechnology Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/224 trials | ||||||
| Phase 1/2 | NCT07396155 | Jul 2026 → Jul 2027 expected | diabetic kidney disease | PT. Prodia Stem Cell Indonesia | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06501066 | Jun 2024 → Dec 2026 expected | — | Meribank Biotech Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05741099 | Jan 2023 → Jan 2024 | COVID-19 | Hebei Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05008588 | May 2022 → Mar 2026 overdue | ischemic stroke | PT. Prodia Stem Cell Indonesia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04919135 | Oct 2021 → Apr 2023 | — | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT04314687 | Oct 2021 → Jul 2026 overdue | cerebral palsy | PT. Prodia Stem Cell Indonesia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03745417 | Aug 2021 → Aug 2022 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT05152160 | Aug 2021 → Aug 2024 | graft versus host disease | Shenzhen University General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04326959 | Sep 2020 | keloid | PT. Prodia Stem Cell Indonesia | Unknown | No outcome recorded |
| Phase 1/2 | NCT04433104 | Jun 2020 → Jul 2021 | chronic obstructive pulmonary disease | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 1/2 | NCT04355728 | Apr → Oct 2020 | COVID-19, acute respiratory distress syndrome | Camillo Ricordi | Completed | No outcome recorded |
| Phase 1/2 | NCT04441658 | Apr 2020 → Jul 2022 | type 2 diabetes mellitus | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02776943 | Jun 2016 → Dec 2018 | articular cartilage disorder, osteoarthritis, knee | South China Research Center for Stem Cell and Regenerative Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT02666391 | May 2016 → Dec 2017 | acute myocardial infarction, cardiomyopathy | South China Research Center for Stem Cell and Regenerative Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT02192749 | Jul 2014 → Aug 2017 | autism | Translational Biosciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02287831 | Feb 2014 → Dec 2022 | peripheral arterial disease | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1/2 | NCT02034188 | Jan 2014 → Mar 2016 | multiple sclerosis | Translational Biosciences | Completed | No outcome recorded |
| Phase 1/2 | NCT01985464 | Oct 2013 → Dec 2019 | rheumatoid arthritis | Translational Biosciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01954147 | Oct 2013 → Oct 2014 | type 2 diabetes mellitus | Diabetes Care Center of Nanjing Military Command | Unknown | No outcome recorded |
| Phase 1/2 | NCT01216865 | Jan 2011 → Dec 2012 | limb ischemia | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01224327 | Oct 2010 → Oct 2012 | cirrhosis of liver | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01219452 | Oct 2010 → Nov 2012 | dilated cardiomyopathy | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01221428 | Sep 2010 → Sep 2012 | ulcerative colitis | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01219465 | Sep 2010 → Sep 2012 | type 1 diabetes mellitus | Qingdao University | Unknown | No outcome recorded |
| Phase 26 trials · 1 met primary | ||||||
| Phase 2 | NCT07441226 | Aug 2025 → Dec 2027 expected | chronic obstructive pulmonary disease | RSUP Persahabatan | Recruiting | No outcome recorded |
| Phase 2 | NCT05719012 | Apr → Dec 2023 | long COVID-19 | Shanghai East Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03505034 | Sep 2019 → Dec 2021 | spinal cord injury | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03521323 | Sep 2019 → Dec 2021 | spinal cord injury | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03521336 | Sep 2019 → Dec 2021 | spinal cord injury | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2 | NCT02302599 | Jan 2013 → Dec 2020 | type 2 diabetes mellitus | Chinese PLA General Hospital | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04972890 | Oct 2020 → Dec 2022 | erectile dysfunction, urinary system disorder | Indonesia University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05682586 | Jan → Mar 2023 | pneumonia | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06388447 | Dec 2023 → Dec 2024 | gingival recession | University of Malaya | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06242405 | Mar 2024 → Dec 2025 | liver disorder | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| — | NCT06167473 | Nov 2023 → Dec 2025 | liver failure | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| — | NCT03724617 | Oct 2018 → Jun 2020 | adhesions of uterus | Sir Run Run Shaw Hospital | Completed | No outcome recorded |
| — | NCT03336996 | Mar 2018 → Mar 2020 | — | General Hospital of Ningxia Medical University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-04 | CytoMed Therapeutics Pte Ltd | CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair cytomed.sg ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 49 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Mesenchymal Stem Cells | “This study aims to determine the efficacy, mechanism of action, and safety of umbilical cord mesenchymal stem cells as a therapy for ED due to type 2 diabetes in human.” NCT04972890 ↗44“Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease” NCT05152160 ↗ “Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19” NCT05719012 ↗ “the clinical use of umbilical cord mesenchymal stem cells has been approved by FDA” NCT03336996 ↗ “Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus” NCT01954147 ↗ “Transplantation of umbilical cord mesenchymal stem cells” NCT04062136 ↗ |
| Known as | hUC-MSCs | “Human umbilical cord mesenchymal stem cells (hUC-MSCs) support revascularization” PMID 31997819 ↗ Aug 2020 |
| Known as | Human Umbilical Cord-Mesenchymal Stem Cells | “Human Umbilical Cord-Mesenchymal Stem Cells (uc-MSCs) were derived from umbilical cord Wharton jelly” NCT06485648 ↗ |
| Known as | mesenchymal stem cells | “Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.” NCT01219452 ↗ |
| Known as | UCMSC | “A safety and feasibility study was completed on the use of umbilical cord MSC (UCMSC) as a treatment for MS.” PMID 29523171 ↗ Mar 2018 |
| Known as | UCMSCs | “This intervention consists of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) administered under imaging guidance.” NCT07396155 ↗8“allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard frailty treatment” NCT04919135 ↗ “Human Umbilical Cord-Mesenchymal Stem Cells (uc-MSCs) were derived from umbilical cord Wharton jelly” NCT06485648 ↗ “allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention” NCT04433104 ↗ “collagen scaffold/umbilical cord mesenchymal stem cells (CS/UC-MSCs) on this refractory disease.” PMID 34294152 ↗ Jul 2021 “umbilical-cord derived mesenchymal stem cells (UC-MSCs)” NCT04457609 ↗ “human umbilical cord mesenchymal stem cells (UC-MSCs)” NCT02235844 ↗ “umbilical cord mesenchymal stem cells (UC-MSCs)” NCT05682586 ↗ “umbilical cord mesenchymal stem cells (UCMSCs)” NCT02666391 ↗ |
| Known as | umbilical cord MSC | “A safety and feasibility study was completed on the use of umbilical cord MSC (UCMSC) as a treatment for MS.” PMID 29523171 ↗ Mar 2018 |
| Known as | umbilical cord MSCs | “10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage” NCT02668068 ↗ |
| Known as | umbilical cord-derived mesenchymal stem cells | “BACKGROUND: To determine the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in Chinese adults with type 2 diabetes mellitus (T2DM).” PMID 35505375 ↗ May 2022 |
| Known as | UMC119-06-05 | “This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome.” NCT06501066 ↗ |
| Modality | Cell therapy | “umbilical cord mesenchymal stem cells” NCT01143168 ↗ |
| Route | Other | “transplanted through pancreas artery percutaneously” NCT01143168 ↗ |